Free Trial
NASDAQ:PMN

Promis Neurosciences (PMN) Stock Price, News & Analysis

Promis Neurosciences logo
$0.54 0.00 (-0.17%)
As of 01:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Promis Neurosciences Stock (NASDAQ:PMN)

Key Stats

Today's Range
$0.52
$0.55
50-Day Range
$0.39
$1.12
52-Week Range
$0.38
$1.59
Volume
194,665 shs
Average Volume
2.77 million shs
Market Capitalization
$27.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.33
Consensus Rating
Buy

Company Overview

Promis Neurosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

PMN MarketRank™: 

Promis Neurosciences scored higher than 48% of companies evaluated by MarketBeat, and ranked 576th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Promis Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Promis Neurosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Promis Neurosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Promis Neurosciences are expected to grow in the coming year, from ($0.24) to ($0.21) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Promis Neurosciences is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Promis Neurosciences is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Promis Neurosciences has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Promis Neurosciences' valuation and earnings.
  • Percentage of Shares Shorted

    3.15% of the float of Promis Neurosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Promis Neurosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Promis Neurosciences has recently decreased by 72.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Promis Neurosciences does not currently pay a dividend.

  • Dividend Growth

    Promis Neurosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.15% of the float of Promis Neurosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Promis Neurosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Promis Neurosciences has recently decreased by 72.15%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 6 people have searched for PMN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Promis Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Promis Neurosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.11% of the stock of Promis Neurosciences is held by insiders.

  • Percentage Held by Institutions

    50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Promis Neurosciences' insider trading history.
Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Promis Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

PMN Stock News Headlines

Washington Thinks They Own Your Bank Account
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
See More Headlines

PMN Stock Analysis - Frequently Asked Questions

Promis Neurosciences' stock was trading at $0.9478 on January 1st, 2025. Since then, PMN stock has decreased by 43.7% and is now trading at $0.5340.

Promis Neurosciences (NASDAQ:PMN) announced its earnings results on Wednesday, August, 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07.

Promis Neurosciences' top institutional shareholders include Armistice Capital LLC (6.54%). Insiders that own company stock include Madge K Shafmaster, Patrick D Kirwin and Neil Cashman.
View institutional ownership trends
.

Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Promis Neurosciences investors own include PayPal (PYPL), Recursion Pharmaceuticals (RXRX), Pacific Biosciences of California (PACB), Editas Medicine (EDIT), Exscientia (EXAI) and Trimble (TRMB).

Company Calendar

Last Earnings
8/13/2025
Today
8/25/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PMN
CIK
1374339
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$3.00
Potential Upside/Downside
+707.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$2.78 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-266.69%
Return on Assets
-131.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.97
Quick Ratio
0.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.50 per share
Price / Book
1.07

Miscellaneous

Outstanding Shares
51,810,000
Free Float
48,641,000
Market Cap
$27.82 million
Optionable
Not Optionable
Beta
-0.04

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:PMN) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners